title: [Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults].
abstract: OBJECTIVE
  To compare the efficacy and toxicity of the chemotherapeutic regimen containing pirarubicin and mitoxantrone on the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults.
  
  
  METHODS
  In this open prospective multicentre study, we randomly assigned patients with relapsed or refractory AML to receive TAE regimen (pirarubicin+cytarabine+etoposide) versus MAE regimen (mitoxantrone + cytarabine + etoposide). The efficacy and toxicity were compared between the two groups.
  
  
  RESULTS
  56 patients entered this clinical trial. The complete remission (CR) rate on TAE arm was 79.0% versus 55.6% on MAE arm with the overall response (OR) rates of 86.8% versus 88.9%, respectively. The CR was higher on TAE arm (P=0.035) but with no significant difference between the two groups regarding the overall response (OR) rate. The regimens were well tolerated in both groups. Hematologic and non-hematologic toxicity were similar except relatively lower the mean dosage of G-CSF, red blood cells and platelets transfusion on TAE arm. No significant differences were seen between the two groups regarding the overall survival and relapse free survival rates.
  
  
  CONCLUSIONS
  TAE regimen might be an effective salvage therapy in patients with relapsed or refractory AML.
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Jingxia
authors.initials: J
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Hou
authors.forename: Hongguo
authors.initials: H
authors.lastname: Zhao
authors.forename: Enqin
authors.initials: E
authors.lastname: Yang
authors.forename: Xuehong
authors.initials: X
authors.lastname: Ran
authors.forename: Minglin
authors.initials: M
authors.lastname: Wang
authors.forename: Wenzheng
authors.initials: W
authors.lastname: Yu
authors.forename: Ruirong
authors.initials: R
authors.lastname: Xu
authors.forename: Zhencheng
authors.initials: Z
authors.lastname: Wang
authors.forename: Kehong
authors.initials: K
authors.lastname: Bi
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Liu
authors.forename: Sheng
authors.initials: S
authors.lastname: Yang
authors.forename: Jin
authors.initials: J
authors.lastname: Fan
authors.forename: Lingling
authors.initials: L
authors.lastname: Wang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D003609:Dactinomycin; D005047:Etoposide; D004317:Doxorubicin; C027260:pirarubicin; D008727:Methotrexate